RxDoctor Payments Data

John Digiglia, MD

Family Medicine · Lake Charles, LANPI 1497717656

Payments from drug & device makers

$2,551in general payments, 2019–2025

Across 136 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$515
  • AstraZeneca$498
  • AbbVie$427
  • Esperion Therapeutics, Inc.$376
  • Novo Nordisk$344
  • Takeda Pharmaceuticals U.S.A., Inc.$97
  • plus $294 from 11 others

What the payments were for

  • Food & beverage$2,545100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,551 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$252,523
Medicare patients
307
Services billed
14,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$108,525
EliquisApixaban48$55,486
TrulicityDulaglutide33$46,392
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl176$41,674
JardianceEmpagliflozin47$35,173
FarxigaDapagliflozin Propanediol23$28,745
MounjaroTirzepatide29$28,538
SuboxoneBuprenorphine Hcl/Naloxone Hcl41$22,385
JanuviaSitagliptin Phosphate22$19,986
Ezetimibe196$3,664
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$3,297
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid34$3,199
Gabapentin162$2,873
Adderall XrDextroamphetamine/Amphetamine15$2,835
SynthroidLevothyroxine Sodium53$2,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$344$108,525112 claims
Lilly USA, LLCTrulicity, Mounjaro$515$74,93062 claims
PfizerEliquis$53$55,48648 claims
AstraZenecaFarxiga$498$28,74523 claims
AbbVieSynthroid$427$2,72253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →